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Abstract: Human adult mesenchymal stem cells (MSCs) were first identified by Friedenstein et al. when observing a 
group of cells that developed into fibroblastic colony forming cells (CFU-F). Ever since, the therapeutic uses and clinical 
applications of these cells have increased research and interest in this field. MSCs have the potential to be used in tissue 
engineering, gene therapy, transplants and tissue injuries. However, identifying these cells can be a challenge. Moreover, 
there are no articles bringing together and summarizing the cell surface markers of MSCs in adults. The purpose of this 
study is to summarize all the available information about the cell surface characterization of adult human MSCs by 
identifying and evaluating all the published literature in this field. We have found that the most commonly reported 
positive markers are CD105, CD90, CD44, CD73, CD29, CD13, CD34, CD146, CD106, CD54 and CD166. The most 
frequently reported negative markers are CD34, CD14, CD45, CD11b, CD49d, CD106, CD10 and CD31. A number of 
other cell surface markers including STRO-1, SH2, SH3, SH4, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-I, DP, EMA, 
DQ (MHC Class II), CDIO5, Oct 4, Oct 4A, Nanog, Sox-2, TERT, Stat-3, fibroblast surface antigen, smooth muscle 
alpha-actin, vimentin, integrin subunits alpha4, alpha5, beta1, integrins alphavbeta3 and alphavbeta5 and ICAM-1 have 
also been reported. Nevertheless, there is great discrepancy and inconsistency concerning the information available on the 
cell surface profile of adult MSCs and we suggest that further research is needed in this field to overcome the problem. 
Keywords: Bone marrow derived multipotent progenitor cells; cell surface profile; mesenchymal stem cells; surface markers. 
INTRODUCTION 
  About 130 years ago, the German pathologist Cohneim 
proposed the existence of non-hematopoietic stem cells in 
the bone marrow. He suggested that these cells could 
contribute to wound healing as they can be a source of 
fibroblasts [1]. Later, Friedenstein et al. identified human 
adult mesenchymal stem cells when observing a group of 
cells that developed into fibroblastic colony forming cells 
(CFU-F) [2]. Friedenstein provided strong evidence for the 
self-renewal potential of stem cells by demonstrating their 
ability to regenerate heterotropic bone tissue. These findings 
have been confirmed and expanded by many further 
laboratory studies which have shown that the cells isolated 
by Friedenstein can also be found in human bone marrow 
and could differentiate into a range of different mesenchymal 
lineage cells including chondrocytes, adipocytes, myoblasts 
and osteoblasts [1, 3-6]. 
 Simmons  et al. found that stromal cells supporting 
hematopoiesis were different to hematopoietic cells by 
showing that sexmismatched HLA-identical cells from 
patients solely expressed the host genotype [7]. This again 
supports Friendenstein’s findings showing hematopoietic 
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stem cells were physically different from transplanted 
sexmismatched cells capable of heterotropic osseous tissue 
formation [8]. Now that these cells are found to be different, 
research is being done to identify whether there exist specific 
cell surface antigens to identify phenotypic differences 
between mesenchymal and hematopoietic stem cells. Even 
though many mesenchymal stem cell surface antigens have 
been cultured, there have been very few in vivo phenotypic 
characterization of MSCs [9]. Bianco et al. conducted one of 
the first studies with the intention of characterizing MSC-
like cells both histologically and phenotypically. 
Interestingly, it has been shown that a wide range of non-
hematopoietic stem cells exist in the bone marrow and that 
MSC are merely a subset of this population. These include 
“multipotent adult progenitor cells” (MAPCs), “endothelial 
progenitor cells” (EPCs), “marrow-isolated adult mutilinease 
inducible cells” (MIAMI), “ very small embryonic-like stem 
cells” (VSELs) [9-13]. 
 Crisan  et al. has found that multipotent mesenchymal 
stem cells exist in many different human organs [14]. To 
support this fact, it has been shown that MSCs are not 
confined to bone marrow and can also be found in placenta, 
dental pulp, tendons, skeletal muscle, fat, umbilical cord 
blood and amniotic fluid [14-22]. Despite the common belief 
that mesenchymal stem cells are derived from the embryonic 
mesoderm, a recent study by Takashima and colleagues 
showed that the earliest lineage of MSC-like cells are 254    The Open Orthopaedics Journal, 2011, Volume 5  Mafi et al. 
developed, at least in part, from Sox1(+) neuroepithelium 
through a neural crest intermediate stage rather than from 
mesoderm [23]. These cells have been shown to be replaced 
by MSCs in later development. Nagoshi and colleagues have 
recently demonstrated that neural crest-derived cells migrate 
through the bloodstream to the bone marrow [24]. These 
cells are present in the bone marrow and can develop into 
myofibroblasts, glial cells and neurons. Further research is 
needed to assess whether there is a link between cells 
indentified by Friedenstein and those identified by 
Takashima and colleagues [25]. 
  Various studies have demonstrated the potential use if 
MSCs in gene therapy, transplants due to their special 
immunogenic properties and tissue injuries. Current research 
aims at characterizing, expanding and identifying ways to 
keep MSCs in the undifferentiated state, with the intention of 
transplanting them back to repair bone and cartilage [26-31]. 
Phinney and Prockop argue that mesenchymal stem cells 
could form the basis for a highly potent “natural system of 
tissue repair” [32]. Many further experimental models of 
tissue injuries have demonstrated the therapeutic properties 
of MSCs upon exogenous administration [33-37]. Prockop 
pointed out to an interesting fact that in the greater 
proportion of studies, there has been no correlation between 
the therapeutic effectiveness and the engraftment efficacy 
[38]. Furthermore, his findings suggest that the ability to 
repair was secondary to secretion of soluble factors by MSCs 
that changed the environment of the tissue [38]. Adult 
human mesenchymal stem cells have also been shown to 
have non-immunogenic surface antigens, due to possessing 
major histocompatibility complex class I protein (MHC I) 
instead of MHC II [39]. This is undoubtedly a valuable 
characteristic of adult MSCs which could make it possible to 
transplant them into an allogenic host without any need for 
immunosuppression [25]. Many attempts have also been 
done in order to apply MSCs in gene therapy. This includes 
their application in Lobstein disease in humans upon 
systemic administration [40, 41]. Nevertheless, extensive 
research needs to be done in this field, as our knowledge 
about their potential use in gene therapy is still very 
primitive. Also, not much is known about the phenotypic 
character, developmental origin and their contribution to 
organogenesis; an assay to demonstrate their self-
renewability in vivo is still missing [25]. 
  The therapeutic uses and clinical applications of MSCs 
have increased research and interest in identifying these 
cells. Despite 1% of the bone marrow population consisting 
of hematopoietic cells only 1/10000 to 1/100000 of the bone 
marrow nuclear cells are MSCs [42, 43]. Moreover, there is 
not adequate information about the cell surface markers of 
adult mesenchymal stem cells and how they can be 
identified. Therefore, correct identification of these cells can 
be a challenge. There are no articles bringing together and 
summarizing the cell surface markers of mesenchymal stem 
cells in adults. The purpose of this study is to summarize all 
the available information about the cell surface 
characterization of adult human mesenchymal stem cells by 
identifying and evaluating all the published literature in this 
field. The studies reporting mesenchymal stem cell surface 
markers were searched predominantly using Medline, 
CINAHL (EBSCO), ZETOC, PubMed, EMBASE and   
 
AMED. This systematic review is intended to provide a good 
basis for identification and selection of adult human 
mesenchymal stem cells. 
MATERIALS AND METHOD 
  The studies referencing the cell surface markers of adult 
mesenchymal cells were searched using the electronic 
databases Medline, CINAHL (EBSCO), ZETOC, PubMed, 
EMBASE, AMED, PREMEDLINE In-Process & Non-
Indexed Citations (OvidSP), ASSIA (CSA Illumina), 
Conference Proceedings Citation Index: Science (ISI) on 
Web of Knowledge, PsycINFO (OvidSP), Science Citation 
Index (ISI) on Web of Knowledge, Social Sciences Citation 
Index (ISI) on Web of Knowledge and Cochrane Library 
(Wiley). The following keywords were used to cite relevant 
articles: adult mesenchymal stem cells, bone marrow-derived 
multipotent progenitor cells, cell surface profile, MSCs, 
surface markers. The inclusion criteria were based on 1) 
characterization of cell surface markers of mesenchymal 
stem cells 2) identifying mesenchymal stem cells in adults. 
Studies were excluded which 1) did not comment on the cell 
surface character of mesenchymal stem cells 2) did not 
involve mesenchymal stem cells 3) identified mesenchymal 
stem cells in non adults, or embryo 4) were not available for 
free viewing. A total of 138 articles were reviewed. 29 
articles were identified as relevant according to the inclusion 
criteria. These studies were summarized and the relevant 
information is presented in Tables 1-5. 
RESULTS 
  29 studies were identified as relevant according to the 
inclusion criteria, out of the 138 articles reviewed. 
Subsequently, these were reviewed carefully and the results 
summarized in Tables 1 and 2. 
  As can be seen in Table 1, twenty nine studies looked at 
mesenchymal cells from different tissues and also identified 
various cell surface markers characterizing the cells. For 
easier interpretation, the cell surface markers identified by 
each study were summarized in Table 2. Gronthos et al. [45] 
stated that adult human bone marrow stromal stem cells 
(BMSSCs) or mesenchymal stem cells are non-cyclical and 
express telomerase activity [45]. Tsai et al. [19] identified 
the expression of SH2, SH3, SH4 and HLA-ABC (MHC 
class I)  in addition to CD29, CD44, CD90, CD105. They 
also found that these multipotent mesenchymal stem cells 
lack expression of HLA-DR, DP, DQ (MHC class II) and 
EMA. Another study by Gronthos et al. [48] reported that 
Human adipose tissue-derived stromal cells lack the 
expression of STRO-1 marker [48]. Positive expression 
STRO-1 marker was identified by Zuk et al. [50], Miura et 
al. [51], Kadar et al. [56], Gronthos et al. [63], Gronthos et 
al. [64], Stewart et al. [65], Simmons et al. [66] and Walsh 
et al. [68]. Igura et al. [21] found that placenta-derived 
mesenchymal progenitor cells (PDMPC) express CD105; 
HLA class I and lack expression of HLA-DR. Zuk et al. [50] 
reported that mesenchymal stem cells were SH2(+), SH3(+). 
Parte  et al. [52] found putative stem cells of menopausal 
human ovarian surface epithelium to be positive for 
pluripotent gene transcripts Oct-4, Oct-4A, Nanog, Sox-2, 
TERT, Stat-3. Yu et al. [55] reported that there is a low 
expression of CD45 and CD44 in Adipose-derived   
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Table 1.  Summary of the Relevant Studies 
 
Study  Type of Cell in Study  Cell Surface Character 
Dominici et al. [44]  Multipotent mesenchymal stromal cells 
These must express CD105, CD73 and CD90, and lack 
expression of CD45, CD34, CD14 or CD11b, CD79alpha or 
CD19 and HLA-DR surface molecules 
Gronthos et al. [45]  Adult human bone marrow stromal stem cells   Express telomerase activity in vivo  
Ohgushi et al. [46]  Mesenchymal stem cells 
Cells were negative for hematopoietic markers (CD14, CD34, 
CD45) but positive for markers present in mesenchymal cells 
CD13, CD29, CD90 
Wongchuensoontorn et al. [47]  Mesenchymal stem cells  Found a population of CD34 and CD45 negative cells which 
were positive for CD44, CD73 and CD105 
Gronthos et al. [48]  Human adipose tissue-derived stromal cells 
CD9, CD10, CD13, CD29, CD34, CD44, CD 49(d), CD 49(e), 
CD54, CD55, CD59, CD105, CD106, CD146, and CD166. But 
no STRO-1 antigen was found as in human adipose tissue 
derived stromal cells 
Tsai et al. [19]  Multipotent mesenchymal stem cells 
Positive for SH2, SH3, SH4, CD29, CD44 and HLA-ABC 
(MHC class I), low positive for CD90 and CD105, but negative 
for CD10, CD11b, CD14, CD34, CD117, HLA-DR, DP, DQ 
(MHC class II) and EMA 
Zvaifler et al. [49]  Mesenchymal precursor cells found in the blood 
A minority of adult marrow cells express CD34 
BMPCs stained strongly with anti-CD44 antibody. 
Conventional T-cell (CD3), monocyte (CD14, CD68), and B-
cell (CD20) antibodies stained neither of the two BMPC 
populations, nor did they react to anti-LCA (CD45), anti-
VCAM (CD106), or MHC-Class II (anti-DR) [49]  
Igura et al. [21]  Placenta-derived mesenchymal progenitor cells 
(PDMPC) 
The PDMPC expressed CD13, CD44, CD73, CD90, CD105 and 
HLA class I as surface epitopes, but not CD31, CD34, CD45 
and HLA-DR. 
Zuk et al. [50]  Mesenchymal stem cells 
Cells expressed CD29, CD44, CD71, CD90, and CD105/SH2 
and SH3, expressed STRO-1. No expression of CD31, CD34, 
and CD45. Positive expression of CD13 and the absence of 
CD14, CD16, CD56, CD61, CD62(e), CD104 and CD106. 
CD49(d) was not observed in MSC culture. However MCS 
expressed CD106 antigen. 
Miura et al. [51]  Stem cells from human exfoliated deciduous teeth 
(SHED) 
SHED were found to express the cell surface 
molecules STRO-1 and CD146, which are cell surface markings 
of adult bone marrow-derived stromal stem cells. 
Parte et al. [52]  Putative stem cells of menopausal human ovarian 
surface epithelium 
Pluripotent gene transcripts Oct-4, Oct-4A, Nanog, Sox-2, 
TERT, Stat-3 in human. 
Iwata et al. [53]  Human bone marrow-derived mesenchymal stem 
cells  CD29, CD44, CD90 and CD90 
Hasebe et al. [54]  Dermal tissue stem cells  Express CD44, CD54, CD90, CD105 and CD271 which are 
stem cell markers.  
Yu et al. [55]  Adipose-derived stromal/stem cells  CD29(+) CD34(+), CD44(lo) CD45(low) CD73(+) CD90(+) 
CD105(+) 
Kadar et al. [56]  Mesenchymal stem cells  STRO-1 positive 
Kyurkchiev et al. [57]  Multipotent endometrial stromal cells and 
multipotent decidual stromal cells  Express surface molecules CD73, CD90 and CD105 
Royer-Pokora et al. [58]  Mesenchymal stem cells  CD105, CD90 and CD73. 
Mousavi et al. [59]  Mesenchymal stem cells 
Expression of CD105, CD166 and CD44, and the absence of 
CD45, CD34 and CD14 on the surface of mesenchymal stem 
cells like cells 
Orciani et al. [60]  Mesenchymal stem cells from human skin biopsies 
(S-MSCs) 
Expression of HLA-A, B, C, CD29, CD44, CD73 and CD90, 
was strongly positive, while CD105 was low positive, and 
CD10, CD11b, CD14, CD34, CD49d and HLA-DR were 
negative 
Bühring et al. [61]  Mesenchymal stem cells in bone marrow  CD13, CD15, CD73, CD140b, CD144, CD146 and CD164 
Latif et al. [62]  Mesenchymal stem cells and human cardiac valve 
ICs (interstitial cells) 
Expressed fibroblast surface antigen, smooth muscle alpha-
actin, vimentin and CD44. CD105 was weakly expressed by 
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stromal/stem cells (ASC). Orciani et al. [60] identified the 
MSCs from human skin biopsies (S-MSCs) to be positive for 
HLA-A, B, C, and low positive for 105 and negative for 
HLA-DR. Latif et al. [62] reported mesenchymal stem cells 
to be positive for fibroblast surface antigen, smooth muscle 
alpha-actin, vimentin and low positive for CD105. Zvaifler 
et al. [49] found that only a minority of bone marrow cells 
expressed CD34. Conget and Minguell [69] reported the 
expression of integrin subunits alpha4, alpha5, beta1, 
integrins alphavbeta3 and alphavbeta5, ICAM-1, and 
CD44H in human bone marrow mesenchymal progenitor 
cells. 
DISCUSSION 
  In this systematic review we have looked at the cell 
surface characterization of adult mesenchymal stem cells. 
We have found that CD105, CD90, CD44, CD73, CD29, 
CD13, CD34, CD146, CD106, CD54 and CD166 rank 
among the most commonly reported positive cell surface 
markers on mesenchymal cells. There are, however, a 
number of cell surface markers that have been reported as 
being absent in mesenchymal stem cells. The most 
frequently reported are CD34, CD14, CD45, CD11b, 
CD49d, CD106, CD10 and CD31. In addition to these, a 
number of other cell surface markers have been identified. 
These are STRO-1, SH2, SH3, SH4, HLA-A, HLA-B, HLA-
C, HLA-DR, HLA-I, DP, EMA, DQ (MHC Class II), 
CDIO5, Oct 4, Oct 4A, Nanog, Sox-2, TERT, Stat-3, 
fibroblast surface antigen, smooth muscle alpha-actin, 
vimentin, integrin subunits alpha4, alpha5, beta1, integrins 
alphavbeta3 and alphavbeta5 and ICAM-1 [19, 21, 50, 50-
52, 56, 60, 62-66, 68, 69]. Eight studies have confirmed the 
expression of STRO-1on bone marrow-derived 
mesenchymal stem cells [50, 51, 56, 63-66, 68]. However, 
Gronthos  et al. [48] has reported adipose tissue-derived 
stromal cells to be STRO-1 negative. This suggests the 
difference in the expression of STRO-1 depending on 
whether they are adipose tissue-derived or bone marrow 
derived; nevertheless it should be noted that these represent 
only about 3% of the bone marrow stromal population [48, 
63-68]. Positive expression of SH2 and SH3 has been 
(Table 1) contd….. 
Study  Type of Cell in Study  Cell Surface Character 
Gronthos et al. [63]  Bone marrow derived stromal progenitor cells   STRO-1 positive 
Gronthos et al. [64]  Stromal cells derived from the bone marrow  STRO-1 positive 
Stewart et al. [65]  Bone marrow-derived mesenchymal stem cells  STRO-1 positive 
Simmons and Torok-Storb [66]  BM-derived mesenchymal stem cells STRO-1 
positive + CD34 positive  STRO-1 positive, CD34 positive 
Simmons et al. [67]  Bone marrow derived mesenchymal stem cells  CD106 positive, CD34 positive 
Walsh et al. [68]  Bone marrow-derived mesenchymal stem cells  STRO-1 positive 
Conget and Minguell [69]  Human bone marrow mesenchymal progenitor cells 
Express integrin subunits alpha4, alpha5, beta1, integrins 
alphavbeta3 and alphavbeta5, ICAM-1, and CD44H. These 
were CD49d (-) and CD34 (-). 
Pittenger et al. [6]  Adult human mesenchymal stem cells  CD49d (-), CD106 (+), CD34 (-) 
Table 2.  Summary of Positive Cell Surface Markers of Mesenchymal Stem Cells 
 
Study CD9    CD10 CD13 CD15 CD29 CD34 CD44 CD44h CD45 CD49(d) CD49(e) CD54 CD55 CD71 CD73 CD90 CD105 CD106  CD140(b) CD144 CD146 CD164 CD166  CD271 
Dominici et al.  [44]                       CD73  CD90  CD105               
Ohgushi et al.  [46]      CD13    CD29                  CD90                 
Wongchuensoontorn et al.  [47]          CD44              CD73    CD105               
Gronthos et al.  [48]  CD9 CD10 CD13    CD29 CD34 CD44      CD49(d) CD49(e) CD54 CD55        CD105        CD146    CD166   
Tsai et al.  [19]        CD29    CD44               CD90  CD105               
Zvaifler et al.   [ 4 9 ]          C D 3 4                                  
Igura et al.  [21]      CD13      CD44              CD73  CD90  CD105               
Zuk et al.  [50]     CD13  CD29  CD44             CD71  CD90  CD105               
Miura et al.  [51]                                 CD146       
Iwata et al.  [53]        CD29    CD44               CD90                 
Hasebe et al.  [54]          CD44          CD54      CD90  CD105              CD271 
Yu et al.  [55]          CD29 CD34 CD44    CD45            CD73 CD90 CD105               
Kyurkchiev et al.  [57]                       CD73  CD90  CD105               
Royer-Pokora et al.  [58]                       CD73  CD90  CD105               
Mousavi et al.  [59]          CD44                CD105            CD166   
Orciani et al.  [60]         CD29  CD44               CD73  CD90  CD105               
Bühring et al.  [61]      CD13  CD15                  CD73        CD140(b)  CD144  CD146  CD164     
Latif et al.  [62]          CD44                               
Simmons  PJ,  Torok-Storb  B  [66]         CD34                                 
Simmons et al.  [67]         CD34                    CD106             
Conget et al.  [69]           CD44h                             
Pittenger et al.   [ 6 ]                            C D 1 0 6                Cell Surface Characterization  The Open Orthopaedics Journal, 2011, Volume 5    257 
confirmed by Tsai et al. [19] and Zuk et al. [50]. Igura et al. 
[21] Tsai et al. [19] and Orciani et al. [60] have all 
confirmed that mesenchymal stem cells are HLA-DR 
negative. Orciani et al. [60] and Latif et al. [62] have both 
stated that there was low expression of CD105. Another 
interesting finding in this systematic review is that several 
studies have reported conflicting findings about the cell 
surface markings of mesenchymal stem cells. These cells 
were identified as CD10 (+) by Gronthos et al. [45], but as 
CD10 (-) by Tsai et al. [19] and Orciani et al. [60]. Similarly 
Gronthos et al. [45], Zvaifler et al. [49] and Yu et al. [55] 
identified the cells as CD34 (+) whereas Dominici et al. [44], 
Ohgushi et al. [46], Wongchuensoontorn et al. [47], Tsai et 
al. [19], Igura et al. [21], Zuk et al. [50], Mousavi et al. [59] 
and Orciani et al. [60] found these to be CD34 (-). 
Table  4.  The Mesenchymal Cell Positive Surface Markers 
and the Number of Studies where they have been 
Reported 
 
CD105 12 
CD90 11 
CD44 11 
CD73 8 
CD29 7 
CD13 5 
CD34 5 
CD146 3 
CD106 2 
CD54 2 
CD166 2 
CD9 1 
CD10 1 
CD15 1 
CD45 1 
CD49d 1 
CD49e 1 
CD55 1 
CD71 1 
CD140b 1 
CD144 1 
CD164 1 
CD271 1 
CD44h 1 
Table 5.  The Cell Surface Markers that have been Reported 
as being Absent on Mesenchymal Stem Cells and the 
Number of Studies that Reported this 
 
CD34 10 
CD14 7 
CD45 6 
CD11b 3 
CD49d 3 
CD106 2 
CD10 2 
CD31 2 
CD62e 1 
CD68 1 
CD117 1 
CD19 1 
CD3 1 
CD16 1 
CD35 1 
CD44 1 
CD49 1 
CD56 1 
CD61 1 
CD104 1 
CD79 1 
 
  In a study to identify the mesenchymal precursor cells in 
the blood of normal individuals, Zvaifler and colleagues 
reported on interesting observations. They found that only a 
minority of these cells express the CD34 surface antigen 
[49]. They also reported that only 5% of marrow cells 
reacted with Stro-1 antigen which is one of the defining 
features of bone marrow MSCs [49, 66]. Moreover, Zvaifler 
et al. stated that the colony forming unit fibroblasts 
expressed much lower levels of CD34 compared to human 
hematopoietic stem cells [49]. Other studies have found that 
CD34 is also expressed on vascular endothelial cells, 
basement membrane structures, and dendritic and 
perifollicular cells in human skin [70, 71]. Simmons and 
Torok-Storb used the expression of CD34 marker to separate 
human bone marrow cells [72]. As suggested by Zvaifler et 
al. the difference in findings concerning the CD34 antigen 
could be because all the studies mentioned above were 
Table 3.  Summary of Negative Cell Surface Markers and Mesenchymal Stem Cells 
 
Stud  y    CD3 CD10 CD11b CD14 CD16 CD19 CD31 CD34 CD35 CD36 CD38 CD44 CD45 CD49 CD49d CD50 CD56 CD61 CD62(E) CD68 CD79  CD104 CD106 CD117 
Dominici et al.  [44]     CD11b  CD14  CD19  CD34        CD45              CD79      
Ohgushi et al.  [46]        CD14      CD34  CD35                         
Wongchuensoontorn et al.  [47]             CD34       CD45                     
Tsai et al.  [19]    CD10  CD11b  CD14      CD34                         CD117 
Zvaifler et al.  [49]  CD3      CD14          CD44  CD45            CD68      CD106   
Igura et al.  [21]            CD31  CD34       CD45                     
Zuk et al.  [50]        CD14  CD16  CD31  CD34        CD45  CD49d  CD56  CD61  CD62(E)     CD104  CD106   
Mousavi et al.  [59]        CD14      CD34       CD45                     
Orciani et al.  [60]    CD10  CD11b  CD14      CD34        CD49                   
Conget et al.  [69]             CD34         CD49d                 
Pittnger et al.   [ 6 ]              C D 3 4          C D 4 9 d                  
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conducted on MSCs before the culture [49]. The same 
stromal cells after culture, in vivo, do not react with CD34 
antibodies anymore [72]. Similarly, despite having been 
identified in the endothelial cells of human umbilical vein, 
they have not been found in vitro [73]. According to these 
results we can conclude that the CD34 expression of these 
cells is highly disputed [74, 75]. 
  CD44 is another cell surface marker that has been 
identified as positive [19, 21, 45, 47, 50, 53-55, 59, 60, 62] 
and negative [49]. Yu et al. [55] stated that adult 
mesenchymal stem cells are CD45 positive as opposed to 
findings by Dominici et al. [44], Wongchuensoontorn et al. 
[47], Zvaifler et al. [49], Igura et al. [21], Zuk et al. [50] and 
Mousavi et al. [59] where they have been reported as CD45 
negative. 
  It is important to note that Yu et al. [55] reported adult 
MSCs to express low levels of CD44 and CD45. Gronthos et 
al. [45] found the cells to be CD49d positive, whereas Zuk et 
al. [50] reported them to be CD49d negative. Finally, 
Simmons et al. [67] and Pittenger et al. [6] have identified 
mesenchymal stem cells as CD106 positive but, Zvaifler et 
al. [49] and Zuk et al. [50] have found them to be CD106 
negative. 
  A possible explanation for the conflicting results 
obtained in different papers reviewed is provided in a study 
conducted by Gronthos and colleagues where gene and 
protein expression of human adipose tissue-derived stromal 
cells in their differentiated and undifferentiated states is 
described. The results obtained were then compared to those 
of bone marrow stromal cells as previously defined in the 
literature. As already mentioned in this paper, they found 
that the expression of surface antigen in adipose tissue-
derived stromal cells is not identical to that of bone marrow-
derived stromal cells [48]. In this study, two different 
explanations for the discrepancy in the results have been 
suggested. Firstly, they argue that these differences may be 
due to different proliferative stages of the cells in culture 
[48]. Furthermore, they also state that donor heterogeneity 
could be of importance when comparing adipose tissue-
derived stromal cells with those derived from the bone 
marrow [48]. 
  In this systematic review we have managed to look at 
many different studies which discuss the different cell 
surface markers of adult MSCs. According to the literature 
reviewed, we can say that there is great discrepancy between 
the existence and expression of many cell surface markers 
including CD10, CD34, CD44, CD45, CD49d and CD106, 
which at times makes it difficult to summarize the available 
evidence in order to establish a set of clear-cut criteria for 
identifying these cells. As mentioned earlier, there may be 
different reasons as to why the expression of these surface 
markers differs in a number of studies. However, we suggest 
that further research is needed to identify the cell surface 
profile of adult MSCs. One possibility would be to choose 
adult MSCs of the same origin, say bone marrow-derived 
MSCs, and compare their surface characteristics under the 
same conditions as other reviews have already provided. 
Subsequently, the characteristics of a group of cells of the 
same origin should be assessed under different conditions, 
such as before and after culture, to observe whether there is 
any change in the expression of surface markers. 
  While we hope to have established a good reference for 
identifying the cell surface markers on adult mesenchymal 
stem cells, it is important to point out some limitations of 
this systematic review. 1) The reported cell surface 
characteristics in the studies reviewed were not all derived 
from the same tissue. Some were bone marrow-derived 
[45;50;51;53;56;61;63-66;68], some from skin [54;60] and 
others from endometrium [57], adipose tissue [48;55], 
ovaries [52], deciduous teeth [51] and many other sources. 2) 
Some of the studies included were not specifically aimed at 
identifying the cell surface markers of adult mesenchymal 
cells. These studies simply included the surface markings 
that were identified or compared to other cells. 3) There were 
fewer studies looking at the negative surface markers of 
mesenchymal stem cells compared to those identifying the 
positive cell surface markers. 4) Despite the fact that there 
are not plenty of studies commenting on identifying adult 
mesenchymal stem cells, we could argue that the number of 
studies reviewed is not very large and thus the results need to 
be interpreted with care. 
CONCLUSION 
  In this systematic review we have summarized the 
available research evidence concerning the cell surface 
profile of adult mesenchymal stem cells. The findings have 
been presented in Tables 1-5. Different studies have 
identified various positive and negative surface markers for 
mesenchymal stem cells. Interestingly, several studies have 
reported conflicting information about some of the cell 
surface markers including CD10, CD34, CD44, CD45, 
CD49d and CD106. We can conclude that the expression of 
some surface antigens, such as STRO-1, is dependent on 
whether the cells are adipose tissue-derived or bone marrow-
derived. Another factor accounting for the variability in the 
expression of adult MSC surface markers could be the 
different stages during cell proliferation and culture where 
the markers have been accessed. Despite the exhaustive 
findings of this systematic review, the conflicting evidence 
and inadequate information about several cell surface 
markers, we suggest that further research in this field is 
necessary. 
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